Premium
Commentary on “Cytoskeletal modulators and pleiotropic strategies for Alzheimer drug discovery.” Atorvastatin's effect in Alzheimer's dementia (LEADe) study
Author(s) -
Hey-Hadavi Judith
Publication year - 2006
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2006.08.007
Subject(s) - atorvastatin , citation , dementia , psychoanalysis , library science , computer science , psychology , medicine , pharmacology , disease
2 The efficacy of statins for treating dyslipidemia and preenting complications of coronary artery disease such as myoardial infarctions is well established [1–5], and has lead to apid adoption worldwide. Statins act by inhibiting 3-hydroxy-methylglutaryl coenzyme A (HMG-CoA) reductase, and are rst-line agents for reducing serum total cholesterol and lowensity lipoprotein cholesterol (LDL-C). AD and cardiovascular disease (CVD) share several comon risk factors, and observational studies have suggested that he risk of AD is reduced in patients who receive statin therapy n mid-life. Lowering cholesterol with statins has been shown o reduce -amyloid production and could provide a mechaism for modifying the progression of AD. Alzheimer’s disase (AD) is characterized pathologically by the deposition of xtracellular -amyloid and the accumulation of neurofibrilary tangles. Strategies to delay the onset of progression of AD ave largely targeted the plaques formed by the deposition of -amyloid.. Cholesterol may play an important role in the evelopment and progression of AD. One proposed benefit of tatins is the prevention of Alzheimer’s disease (AD), potenially related to cholesterol reducing [6] and/or anti-inflammaory properties [7]. In animal models, elevated cholesterol evels have been shown to increase processing of amyloid recursor protein (APP) and associated -amyloid production. Randomized, double-blind, placebo-controlled, clinical rials (RCT) sufficiently large to provide definitive evidence or the benefits of statin therapy in AD have not yet been onducted, although a recent pilot RCT suggested that atorastatin improved AD symptoms [8]. Most observational tudies have also reported that statin exposure protects gainst AD [9–13], but two recent studies found no signifcant association between statin use and subsequent onset of ementia or AD [14,15]. The latter two studies controlled
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom